HSBC Initiates Coverage On Actinium Pharma with Buy Rating, Announces Price Target of $11.6
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt has initiated coverage on Actinium Pharma with a Buy rating and a price target of $11.6.
September 06, 2023 | 9:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC has initiated coverage on Actinium Pharma with a Buy rating and a price target of $11.6, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, HSBC's Buy rating and price target of $11.6 for Actinium Pharma could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100